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Abstract
CLN3-Batten disease is a rare, autosomal recessive disorder involving seizures, visual, motor and cognitive decline, and premature 
death. The Cln3 mouse model recapitulates several phenotypic characteristics of the most common 1.02kb disease-
associated deletion. Identification of reproducible biomarker(s) to facilitate longitudinal monitoring of disease progression and 
provide readouts for therapeutic response has remained elusive. One factor that has complicated the identification of suitable 
biomarkers in this mouse model has been that variations in animal husbandry appear to significantly influence readouts. In the 
current study, we cross-compared a number of biological parameters in blood from Cln3 mice and control, non-disease mice 
on the same genetic background from multiple animal facilities in an attempt to better define a surrogate marker of CLN3-Batten 
disease. Interestingly, we found that significant differences between Batten and non-disease mice found at one site were generally 
not maintained across different facilities. Our results suggest that colony variation in the Cln3 mouse model of CLN3-Batten 
disease can influence potential biomarkers of the disease.
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Introduction
Batten disease or Neuronal Ceroid Lipofuscinoses (NCLs) is a family of lysosomal storage disorders sharing the common features 
of neurodegeneration and premature death, which are the result of mutations in as many as 14 different genes [1–3]. The most 
common childhood forms of Batten disease result from mutations in either CLN1 (Classic Infantile Neuronal Ceroid Lipofuscinosis; 
cINCL; Haltia–Santavuori), CLN2 (Classic Late-Infantile Neuronal Ceroid Lipofuscinosis; cLINCL; Janský–Bielschowsky) or CLN3
(Classic Juvenile Neuronal Ceroid Lipofuscinosis; cJNCL; Spielmeyer–Sjögren). Disease onset for these variants ranges from 
infancy to adulthood depending on the affected gene and particular mutation [1, 2]. In this study, we focus on CLN3-Batten disease, 
which has symptomatic onset between 5–10 years of age; it most often begins with progressive blindness and intractable seizures, 
followed by cognitive and motor deterioration, and ultimately premature death by the 20s-early 30s [1]. Although significant 
advances in the treatment of other lysosomal storage disorders have been made over the last decade, therapeutics for 
CLN3-Batten disease do not currently exist [4]. However, over the last several years a number of clinical trials have been initiated 
for some of the NCLs (NCT01399047, NCT01161576, NCT01414985, NCT01907087, NCT00151216, NCT00337636, 
NCT00028262, NCT01238315, NCT02725580; ClinicalTrials.gov; reviewed in [4]) and, more recently, the FDA approved the first 
treatment for CLN2-Batten disease, an enzyme replacement therapy called Brineura[5].
Given the limited number of Batten disease patients [an estimated one in 12,500 live births in Anglo-Saxon countries and one in 
100,000 worldwide (reviewed in [2, 6, 7]], there are a number of unique challenges facing researchers in the successful design of 
clinical trials studying such rare diseases. One advantage within the Batten disease community is access to a well-documented 
natural history of the various forms of the disease [1]. Additionally, comprehensive clinical rating scales have been developed that 
allow a physician to track patient progression both pre- and post-treatment [8, 9]. Furthermore, with advances in neurological 
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imaging, clinicians have formulated metrics for monitoring MRI, CT or PET scans in patients enrolled in clinical trials. Unfortunately, 
these techniques often require sedation, which is extremely stressful for pediatric patients; further confounding the outcomes of 
clinical trials. Thus, the Batten disease field is still searching for reliable, non-invasive, biological parameters for tracking disease 
progression. Surrogate markers of disease (i.e., biomarkers) are useful tools that allow clinicians to collect patient tissue samples 
(i.e., blood or urine, buccal swabs, and skin biopsies) with minimal to no sedation, and to monitor changes over time. Identification 
of easily assessable disease markers is needed for the advancement of Batten disease therapeutic discovery. Preliminary 
feasibility of this approach has been previously demonstrated in hematological proteins in human Batten disease patient blood 
samples [10].
To expedite the identification of useful surrogate markers, we and others have turned to a mouse model of CLN3-Batten disease. 
CLN3 is a transmembrane lysosomal/late endosomal protein of unknown function, although its cellular localization suggests a 
putative role in endocytosis, autophagy, lysosomal transport, and/or apoptosis [11]. The Cln3 mouse model encompasses the 
most common CLN3 mutation, namely a 1.02 kb deletion spanning exons 7 and 8 of CLN3[12–14]. This mouse model also 
recapitulates many phenotypic similarities with human CLN3-Batten disease, including accumulation of autofluorescent storage 
material, neuronal degeneration, glial activation, and behavioral deficits[12, 15–17]. In an attempt to identify surrogate markers 
aimed at tracking CLN3-Batten disease progression, Staropoli et al. utilized a comprehensive panel of biochemical assays to 
analyze peripheral tissues of Cln3 mice [18]. They reported changes in serum ferritin concentrations, red blood cell (RBC) 
mean corpuscular volume (MCV), and reticulocyte counts as well as decreased T cell numbers (the latter in male mice only) in 
Cln3 compared to wild-type mice [18].
While the search for relevant biomarkers has been encouraging, it has become increasingly evident over the past several years 
that disease markers in animal models, including Cln3 mice, can be affected not only by age, gender, and genetic background 
of the test animals, but also by seemingly innocuous differences in environmental conditions [19, 20]. Thus, for CLN3-Batten 
disease surrogate biomarkers to have the broadest utility in clinical applications, they must correlate with the disease regardless of 
the confounding effect of differing external factors. In this study, we explored whether the potential biomarkers of CLN3-Batten that 
have been previously identified remain consistent across Cln3 mice raised and housed at different research institutions (i.e., 
colonies in South Dakota, Nebraska, and Illinois), and also tested for new biomarkers that may be robust in predicting disease [18].
Materials and methods
Animal use
Animal protocols were approved by the Institutional Animal Care and Use Committees of each participating institute [NIH/OLAW 
Assurance Number: A4568-01 (Sanford); A3279-01 (Rosalind Franklin); A3294-01 University of Nebraska Medical Center)], with all 
procedures conducted in strict accordance with National Institutes of Health guidelines and Institutional Animal Care and Use 
Committee Guidelines at each of the three institutions. Wild-type and homozygous Cln3 mice, developed by Cotman et al. [12] 
on a C57BL/6J background, were initially obtained from Jackson Laboratory by Sanford Research and animals from this parental 
colony were then distributed to laboratories at Rosalind Franklin University of Medicine and Science and The University of 
Nebraska Medical Center. The mice used at Rosalind Franklin University of Medicine and Science were two to three generations 
from the Sanford/Jackson Laboratory founders, and the mice used at The University of Nebraska Medical Center were five to eight 
generations from the Sanford/Jackson Laboratory founders. Given male Batten disease patients often present with an earlier 
disease phenotype, and the Batten disease field has historically studied primarily male mice, for the studies presented here only 
male mice were used [1, 21, 22]. Animals housed at Sanford Research utilized irradiated Teklad 2018 chow (ad libitum), non-
acidified water (ad libitum), Teklad 7092–7097 corncob bedding, and Teklad 7099 laboratory animal bedding as enrichment 
(Teklad, East Millstone, NJ). Mice were exposed to a 12-hour light/dark cycle. Animals from Rosalind Franklin University were 
provided with irradiated Envigo Teklad 2019S Global 19% protein extruded rodent diet, water filtered by reverse osmosis and 
delivered using a central Edstrom automated watering system (ad libitum), and Harlan 7090 Sani Chips-Aspen bedding, as well as 
Ancare cotton Nestlets (NES3600) and mouse walk up huts (Otto Environmental, JW-82100) for enrichment and exposed to a 12-
hour light/dark cycle. Animals from the University of Nebraska Medical Center were provided with autoclaved Teklad Diet 2019 (ad 
libitum) and non-acidified water packaged using a Hydropac Watering System (Lab Products, Inc., Seaford, DE), and Bed ‘O cobs 
¼ inch (The Andersons Inc., Maumee, OH) autoclaved bedding.
Complete blood counts
A total of 61 mice from two of the colonies (32 from the University of Nebraska Medical Center, and 29 from Sanford Research) 
were analyzed for complete blood counts (CBC’s) at 1, 3, 6, and 12 months-of-age. Submandibular blood collection was performed 
as previously described [23]. Briefly, mice were restrained, and a lancet was used to puncture the submandibular vein for blood 
collection into EDTA-coated microtainer tubes (BD, Franklin Lakes, NJ). All samples were analyzed on the day of collection. CBC’s 
were performed using a Scil Vet ABC Hematology Analyzer following the manufacturer’s suggested protocol with the mouse 
species card (Scil Vet, Gurnee, IL).
Clinical blood chemistry profiling
A total of 28 mice from three different colonies (Four each of mutant, homozygous Cln3 and wild-type from the University of 
Nebraska Medical Center, 10 from Rosalind Franklin University, and five each of mutant and wild-type from Sanford Research), all 
5 months of age, were sent to Charles River Laboratories for clinical chemistry testing. Serum was analyzed for the following 
metabolites and biomarkers: Alanine aminotransferase, Albumin, Alkaline phosphatase, Aspartate aminotransferase, Bilirubin 
(total), Blood Urea Nitrogen, Calcium, Chloride, Cholesterol (Total), Creatinine, Ferritin, Gamma Glutamyl Transferase, Glucose, 
Inorganic Phosphorus (Phosphate), Iron, Potassium, Sodium, Total Iron Binding Capacity, Total Protein, Transferrin, and 
Triglycerides. These tests are included in the complete and iron clinical chemistry panels at Charles River Laboratories 
(http://www.criver.com/products-services/safety-assessment/pathology/clinical-pathology).
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Statistics were performed using GraphPad Prism 6.04 and R 3.5.0. Specific statistical tests used are indicated in the figure legends. 
In general, either an unpaired, two-tailed t-test,ordinary two-way ANOVA, or ordinary three-way ANOVA was employed (reporting 
type III sum of squares). Statistical outliers were removed with the ROUT method, Q = 1%. For the unpaired, two-tailed t-test, 
variance was determined using the F-test. For the ordinary two-way ANOVA, variance was determined using the Brown-Forsythe 
test and post-hoc analysis was conducted within each individual blood parameter using a Tukey correction in Graph Pad Prism. 
The three-way ANOVA was performed in R 3.5.0 and was followed by Tukey’s Honest Significant Differences post hoc test. All data 
and ANOVA tables are available in S1, S2 and S3 Files. All graphs are presented as mean +/- 95% confidence interval, with mice 
from Sanford Research denoted as Colony 1, mice from The University of Nebraska Medical Center denoted as Colony 2, and mice 
from Rosalind Franklin University of Medicine and Science denoted as Colony 3. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Results
Basic iron panel
Basic iron panels were used to assess hematological differences in iron, ferritin, transferrin, and total iron binding capacity. To 
assess the influence of external factors, the data was separated based on the home institution of the mouse colonies. This 
assessment indicated no significant differences in iron, ferritin, transferrin, or total iron binding capacity between each colony of 
wild-type and Cln3 mice. However, there was a significant interaction between Genotype and Colony on ferritin levels (p = 
0.0249) and a significant main effect of Colony on iron levels (p = 0.0388) (Fig 1A–1D). When data from all three colonies were 
pooled, there were no significant differences detected in any of the parameters measured (Fig 1A–1D, bottom). There were no 
significant changes seen in basic iron panels when comparing control and Cln3 mice within a single colony, the only significant 
difference between control and Cln3 mice was between the control mice of colony 1 and the Cln3 mice of colony 2.
Fig 1. Significant interaction of colony and genotype on ferritin levels between three colonies at 5 months of age.
The basic iron panel values of blood collected from each genotype was analyzed for colonies 1 (blue, Sanford Research), 2 
(black, University of Nebraska Medical Center), and 3 (red, Rosalind Franklin University of Medicine and Science) for both 
control (circle) and Cln3 mice (square). Graphs indicate concentration of iron, (A), total iron binding capacity (B), ferritin 
(C), and transferrin (D), with individual colony data on top and pooled colony data on the bottom. A significant main effect of 
colony was detected on iron levels, p = 0.0388. (A) A significant interaction between colony and genotype was detected on 
ferritin levels, p = 0.0249; the colony factor approached significance at p = 0.0677 and the genotype factor had a p-value of 
0.0922 (C). Data represented as mean ± 95% CI; data points represent individual mice from indicated colony. Statistical 
significance for top graphs was determined using ordinary two-way ANOVA, followed by Tukey’s multiple comparison test 
with a Bonferroni correction. Statistical significance for bottom, pooled colony graphs was determined using an unpaired 
student’s t test. *p<0.05.
https://doi.org/10.1371/journal.pone.0201470.g001
Basic lipid panel
Lipid metabolism of Cln3 mice was assessed by measuring blood levels of cholesterol and triglycerides. When the data was 
separated for individual colonies, there was a significant effect of the animal’s colony on cholesterol and triglyceride levels (p = 
0.0003, p = 0.0344, respectively; Fig 2A and 2B). This is likely due, at least in part, to the difference in lipid concentration across 
different institution diets. When the data from all three colonies were pooled, neither cholesterol nor triglyceride levels were 
significantly altered in Cln3 mice (Fig 2A and 2B). Further study is needed to determine if Cln3 mice possess any lipid 
metabolism defects when presented with different diets or housing conditions.
Fig 2. Colony specific effects on lipid levels in Cln3 and wild-type animals at 5 months of age.
Cholesterol and triglyceride levels were analyzed for colonies 1 (blue, Sanford Research), 2 (black, University of Nebraska 
Medical Center), and 3 (red, Rosalind Franklin University of Medicine and Science) for both control (circle) and Cln3 mice 
(square). Graphs indicate concentration of cholesterol (A) and triglycerides (B), with individual colony data on top and pooled 
colony data on the bottom. There was a significant effect of the animal’s housing colony of measured cholesterol levels (p = 
0.0003, A), and triglyceride levels (p-0.0344, B) Data represented as mean ± 95% CI; data points represent individual mice at 
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indicated colony location. Statistical significance for top graphs was determined using ordinary two-way ANOVA, followed by 
Tukey’s multiple comparison test with a Bonferroni correction. Statistical significance for bottom, pooled colony graphs was 
determined using an unpaired student’s t test. **p<0.01.
https://doi.org/10.1371/journal.pone.0201470.g002
Comprehensive metabolic panel
Next, the metabolic state of Cln3 mice was evaluated by measuring the concentration of 15 different analytes: aspartate 
aminotransferase, alanine aminotransferase, alkaline phosphatase, albumin, total protein, sodium, potassium, sodium to potassium 
ratio, calcium, chloride, glucose, blood urea nitrogen, creatinine, phosphorus, and total bilirubin. Similar blood chemistry analysis 
has been performed on Cln3 mice as a readout of liver, kidney, and pancreatic function [24]. Analysis of the data as separate 
colonies (Fig 3A–3O) showed significant effects of the animal’s housing colony on glucose (p = 0.0090), total protein (p = 0.0439), 
calcium (p = 0.0184), phosphorus (p = 0.0045), potassium (p = 0.0186), and the sodium/potassium ratio (p = 0.0411). This is likely 
a result of the handling differences at each institution, such as diet composition. Interestingly, there was a significant interaction 
between colony and genotype on total bilirubin (p = 0.0289) and creatine levels (p = 0.0040)). When data from all three colonies 
was combined, we saw no significant differences in any of the measured parameters between 5 month-old Cln3 and wild-type 
mice (Panels A-O in S1 Fig).
Fig 3. Colony specific effects and colony:genotype interactions in metabolic parameters between control and Cln3 mutant mice at 5 
months of age.
Metabolic panels measuring blood levels of aspartate aminotransferase (A), alanine aminotransferase (B), alkaline 
phosphatase (C), albumin (D), total protein (E), sodium (F), potassium (G), sodium:potassium ratio (H), calcium (I), chloride 
(J), glucose (K), blood urea nitrogen (L), creatinine (M), phosphorus (N), and total bilirubin (O) were analyzed for colonies 1 
(blue, Sanford Research), 2 (black, University of Nebraska Medical Center), and 3 (red, Rosalind Franklin University of 
Medicine and Science) for both control (circle) and Cln3 mice (square). Colony specific effects were seen in glucose (p = 
0.0090, K), total protein (p = 0.0439, E), calcium (p = 0.0184, I), phosphorus (p = 0.0045, N), potassium (p = 0.0186, G), and 
the sodium/potassium ratio (p = 0.0411, H), with an interaction between genotype and colony seen in total bilirubin (Int p = 
0.0289, Colony p = 0.0493, Genotype p = 0.0484, O) and creatine levels (p = 0.0040, M). Data represented as mean ± 95% 
CI; data points represent individual mice from indicated colony. Statistical significance using ordinary two-way ANOVA, 
followed by Tukey’s multiple comparison test with a Bonferroni correction. *p<0.05.
https://doi.org/10.1371/journal.pone.0201470.g003
Complete blood counts and hematological parameters
Blood collected from Cln3 and wild-type mice was analyzed for complete blood counts (CBCs) at 1, 3, 6, and 12 months-of-
age in two colonies. When data was analyzed on a colony-by-colony basis, some significant variations were detected.
A significant effect of genotype across the two colonies was detected in white blood cell (p = 0.0011), lymphocyte (p = 0.0001), 
platelet (p = 0.0110), and mean platelet volume (p = 0.0215). (Fig 4A, 4B, 4I and 4J). For the majority of the CBC metrics, there 
were a number of metrics where a significant effect of the animal’s housing colony or age was noted (Fig 4A–4L). Most importantly, 
there were a number of instances where a significant interaction between an animal’s housing colony, genotype, and/or age was 
detected, including red blood cell count (Age:Colony p = 0.0406), mean corpuscular volume (Genotype:Age:Colony p = 0.0216, 
Genotype:Age p = 0.0230, Age:Colony p = 3.5 ), mean corpuscular hemoglobin (Genotype:Age:Colony p = 0.0496, Age:Colony p 
= 0.0238), platelet count (Genotype:Age p = 0.0271, Age:Colony p = 0.0111), and lymphocyte count (Age:Colony p = 0.0120) (Fig 
5B, 5E, 5F, 5I and 5J). These results indicate that CBC parameters may be inconsistent across time and colony when comparing 
wild-type and Cln3 mice. When data from the two colonies were pooled, there were no significant differences between aged 
matched wild-type and Cln3 mice in any of the parameters measured. There was, however, a significant main effect of age on 
several of the parameters measured, and a significant main effect of genotype on mean platelet volume (p = 0.0019) (Fig 5A, 5B, 
5E–5L). These findings further support our conclusion that a consistent biomarker is difficult to find across multiple colonies of wild-
type and Cln3 mice.
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Fig 4. Effect of age, genotype, colony, and interaction on blood count parameters between separately housed wild-type and Cln3 mice.
Blood collected from 1, 3, 6, and 12-month-old wild-type and Cln3 mice was assessed for differences in the number of 
total white blood cells (A), lymphocytes (B), monocytes (C), granulocytes (D), RBCs (E), mean corpuscular volume (F), red 
blood cell distribution width (G), hematocrit (H), platelet count (I), mean platelet volume (J), hemoglobin (K), mean corpuscular 
hemoglobin (L), and mean corpuscular hemoglobin concentration (M). Graphs are representative of mice from Sanford 
Research (colony 1) and The University of Nebraska Medical Center (colony 2). A significant effect of genotype across the 
two colonies was detected in white blood cell (p = 0.0011, A), lymphocyte (p = 0.0001, B), platelet (p = 0.0110, I), and mean 
platelet volume (p = 0.0215, J) metrics. There were a number of metrics where a significant effect of the animal’s housing 
colony or age was noted, which are detailed in S1 and S2 Files. There were a number of instances where a significant 
interaction between an animal’s housing colony, genotype, and/or age was detected, including red blood cell count 
(Age:Colony p = 0.0406, E), mean corpuscular volume (Genotype:Age:Colony p = 0.0216, Genotype:Age p = 0.0230, 
Age:Colony p = 3.5 , F), mean corpuscular hemoglobin (Genotype:Age:Colony p = 0.0496, Age:Colony p = 0.0238, L), 
platelet count (Genotype:Age p = 0.0271, Age:Colony p = 0.0111, I), and lymphocyte count (Age:Colony p = 0.0120, B). Data 
represented as mean ± 95% CI; data points represent individual mice from indicated colony. Statistical significance was 
determined using ordinary three-way ANOVA, followed by Tukey’s multiple comparison test with p-values adjusted for 
multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
https://doi.org/10.1371/journal.pone.0201470.g004
Fig 5. Effect of age, genotype, and interaction on blood count parameters between wild-type and Cln3 mice.
Data from 1, 3, 6, and 12-month-old wild-type and Cln3 mice from Colony 1 and Colony 2 were pooled together and 
evaluated for differences in number of white blood cells (A), lymphocytes (B), monocytes (C), granulocytes (D), RBCs (E), 
mean corpuscular volume (F), red blood cell distribution width (G), hematocrit (H), platelet count (I), mean platelet volume (J), 
hemoglobin (K), mean corpuscular hemoglobin (L), and mean corpuscular hemoglobin concentration (M). A significant main 
effect of age was detected on several of the parameters measured and is detailed in S1 File. A significant main effect of 
genotype on mean platelet volume was also detected (p = 0.0019, J). Data represented as mean ± 95% CI; data points 
represent individual mice from indicated colony. Statistical significance was determined using ordinary two-way ANOVA, 
followed by Tukey’s multiple comparison test with a Bonferroni correction. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
https://doi.org/10.1371/journal.pone.0201470.g005
Discussion
Compared to other lysosomal storage disorders, CLN3-Batten disease remains one of the more poorly understood in terms of 
underlying molecular mechanism; the exact function of CLN3 is unknown and with no known enzymatic function it is not amenable 
to enzyme replacement therapy or similar therapeutic approaches [25]. The Cln3 mouse model of CLN3-Batten disease has 
become an invaluable tool for studying disease pathology, as it recapitulates many of the phenotypic characteristics associated with 
human CLN3-Batten disease. However, identification of reproducible, non-invasive, biological surrogate marker(s) that will allow for 
the longitudinal monitoring of disease progression and readouts for therapeutic responses remain elusive. In this work, we utilized 
blood chemistry panels and complete blood counts to compare wild-type and Cln3 mice for differences that might be exploited 
as disease biomarkers. Importantly, we also determined how consistent these parameters were between distinct colony locations 
as the ideal biomarker would be reproducible notwithstanding subtle confounding factors imposed by study location.
There were a number of metrics that were influenced by colony location across both genotypes, though most importantly many of 
these were affected by an interaction of the genotype, colony, and/or age of the animals. These included ferritin (Fig 1C), total 
bilirubin and creatine (Fig 3M and 3O), red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, platelet 
count, and lymphocyte count (Fig 4B, 4E, 4F, 4I and 4L).
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While a previous report by Staropoli et al has suggested altered serum ferritin levels in CLN3-Batten disease mice could be a useful 
biomarker, we did not find significant differences between our three colonies of wild-type and Cln3 mice[18]. Rather, we found 
a significant interaction of genotype and colony on ferritin levels (Fig 2C). It is worth noting that the absolute levels of ferritin, even 
in control mice, varied substantially between these two studies, though when combined with the interaction of genotype and colony 
revealed in our study, this suggests that ferritin may not be a consistent biomarker of CLN3-Batten disease. Similarly, while this 
previous study reported that MCV were elevated in Cln3 mice, no differences in MCV were detected between individual 
colonies of wild-type and Cln3 mice in our current study. Rather, a significant interaction between genotype, age, and/or 
colony was detected (Fig 4F). We note that the mice in the current study were older (5 months of age) at time of metabolic panel 
analysis than those tested in the earlier study from Staropoli et al. (12–19 weeks). This difference in the time of analysis may 
indicate that ferritin levels are elevated in Cln3 mice earlier in life and then stabilize as the mice age. It is also possible that 
strain differences play a role, as we used Cln3 mice in a C57BL/6J background, while Staropoli et al. used the C57BL/6N 
strain. Previous studies have documented phenotypic variation between the J and N inbred strains, including differences in clinical 
blood chemistry, hematology, metabolism, and immune function relevant to many of the parameters we analyzed here, as well as 
neurobehavioral differences [26]. Background selection has a significant impact on other disease markers, such as ocular lesions, 
confounding visual acuity tests commonly performed for Batten disease models [27]. Regardless of potential reasons for the 
discrepancy, in our study, there were no parameters we observed that showed both significant differences between mutant and 
wild-type mice and were observed consistently across multiple colonies.
Our results highlight the importance of standardizing the environment and likely the age of the animals as much as possible when 
searching for relevant biomarkers of genetic diseases. Geographical location of a colony and associated environmental factors 
have been shown to affect body weight, motor coordination, and learning capability in wild-type mice [19]. From the more obvious 
and easily controlled environmental factors such as diet, source of water, and bedding type, seemingly innocuous differences such 
as type of cage, enrichment, number of mice housed per cage, and differences in social hierarchies within cages are all 
environmental factors that can impact the results of animal studies [28–30]. Even changing position of cages on the rack can affect 
temperature, humidity, light and sound intensity a given cage is subject to [31]. Furthermore, animals being compared should come 
from the same source (commercial or otherwise) to minimize variability due to genetic drift. While these factors can be controlled to 
a great extent, different personnel handling mice at each location is one potential confounding variable that is difficult to control; in 
fact, in some behavioral studies, it has been demonstrated that even the gender of the human observer can affect baseline 
responses with respect to measures of pain and anxiety [32]. While the aforementioned studies refer mainly to how environmental 
factors can influence reproducibility in rodent behavioral experiments, importantly, other studies have reported that environmental 
and handling differences can significantly affect mouse physiological parameters such as blood chemistry. For example, number of 
mice housed per cage (2 vs. 4), timing of blood draw (morning vs. afternoon), venipuncture site (tail vein vs. retro-orbital), notably 
altered glucose, triglycerides, and/or iron are all potential variables [33, 34].
Conclusions
In summary, we sought to elucidate reproducible, non-invasive, surrogate biomarkers in the Cln3 mouse model of 
CLN3-Batten disease that could potentially be translated to human patients. Of all the blood chemistry and hematological read outs 
we measured, there were no parameters that were consistently altered between wild-type and Cln3 mice across multiple 
colonies. Further, our findings were inconsistent with previously reported changes reported between wild-type and Cln3 mice 
[18]. A major unmet need for CLN3-Batten research, epidemiology, and therapeutic development is a robust, biologically relevant 
biomarker that can be tracked longitudinally in human patients, where environmental variations are much more substantial and far 
less controllable than in mice. Our results suggest that there is not a robust biomarker for CLN3-Batten disease in commonly tested 
hematological measurements.
Supporting information
S1 Fig. No changes in metabolic parameters between control and Cln3 mutant mice at 5 months of age.
Metabolic panels measuring blood levels of aspartate aminotransferase (A), alanine aminotransferase (B), alkaline phosphatase 
(C), albumin (D), total protein (E), sodium (F), potassium (G), sodium/potassium ratio (H), calcium (I), chloride (J), glucose (K), 
blood urea nitrogen (L), creatinine (M), phosphorus (N), and total bilirubin (O) were pooled for all wild-type and Cln3 mice. No 
differences were observed in any of the molecules when comparing wild-type to Cln3 mice. Data represented as mean ± 95% 
CI; data points represent individual mice (pooled from all three colony locations). Statistical significance was determined using an 
unpaired, two-tailed, Student’s t-test.
https://doi.org/10.1371/journal.pone.0201470.s001
(TIF)
S1 File. Statistical results table from two-way ANOVAs—CBCs.
https://doi.org/10.1371/journal.pone.0201470.s002
(XLSX)
S2 File. Statistical results table from three-way ANOVAs—CBCs.
https://doi.org/10.1371/journal.pone.0201470.s003
(XLSX)
S3 File. Raw data.
https://doi.org/10.1371/journal.pone.0201470.s004
(XLSX)
Δex7/8
Δex7/8
Δex7/8
Δex7/8
Δex7/8
Δex7/8
Δex7/8
Δex7/8
Δex7/8
Δex7/8
Δex7/8
1. 
View Article • PubMed/NCBI • Google Scholar 
2. 
View Article • PubMed/NCBI • Google Scholar 
3. 
View Article • PubMed/NCBI • Google Scholar 
4. 
View Article • PubMed/NCBI • Google Scholar 
5. 
View Article • PubMed/NCBI • Google Scholar 
6. 
View Article • PubMed/NCBI • Google Scholar 
7. 
View Article • PubMed/NCBI • Google Scholar 
8. 
View Article • PubMed/NCBI • Google Scholar 
9. 
View Article • PubMed/NCBI • Google Scholar 
10. 
View Article • PubMed/NCBI • Google Scholar 
11. 
View Article • PubMed/NCBI • Google Scholar 
12. 
View Article • PubMed/NCBI • Google Scholar 
13. 
View Article • PubMed/NCBI • Google Scholar 
14. 
View Article • PubMed/NCBI • Google Scholar 
15. 
View Article • PubMed/NCBI • Google Scholar 
16. 
View Article • PubMed/NCBI • Google Scholar 
17. 
References
Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and natural history of the neuronal ceroid lipofuscinoses. Journal of child 
neurology. 2013;28(9):1101–5. Epub 2013/07/11. pmid:23838030. 
Chabrol B, Caillaud C, Minassian B. Neuronal ceroid lipofuscinoses. Handbook of clinical neurology. 2013;113:1701–6. Epub 2013/04/30. pmid:23622391. 
Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta. 2015;1852(10 Pt B):2237–41. 
pmid:26026925. 
Geraets RD, Koh S, Hastings ML, Kielian T, Pearce DA, Weimer JM. Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. 
Orphanet journal of rare diseases. 2016;11:40. Epub 2016/04/17. pmid:27083890. 
Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, et al. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N Engl J Med. 
2018. pmid:29688815. 
Boustany R-MN. Lysosomal storage diseases—the horizon exapnds. Nature Reviews Neurology. 2013;9:583–98. pmid:23938739 
Haltia M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta. 2013;1832(11):1795–800. Epub 2012/09/11. 
pmid:22959893. 
Adams HR, Beck CA, Levy E, Jordan R, Kwon JM, Marshall FJ, et al. Genotype does not predict severity of behavioural phenotype in juvenile neuronal 
ceroid lipofuscinosis (Batten disease). Dev Med Child Neurol. 2010;52(7):637–43. Epub 2010/03/02. pmid:20187884. 
Marshall FJ, de Blieck EA, Mink JW, Dure L, Adams H, Messing S, et al. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. 
Neurology. 2005;65(2):275–9. Epub 2005/07/27. pmid:16043799. 
Hersrud SL, Geraets RD, Weber KL, Chan CH, Pearce DA. Plasma biomarkers for neuronal ceroid lipofuscinosis. FEBS J. 2016;283(3):459–71. 
pmid:26565144. 
Carcel-Trullols J, Kovacs AD, Pearce DA. Cell biology of the NCL proteins: What they do and don’t do. Biochim Biophys Acta. 2015;1852(10 Pt B):2242
–55. pmid:25962910. 
Cotman SL, Vrbanac V, Lebel LA, Lee RL, Johnson KA, Donahue LR, et al. Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit 
progressive neurologic disease that begins before birth. Hum Mol Genet. 2002;11(22):2709–21. Epub 2002/10/11. pmid:12374761. 
Munroe PB, Mitchison HM, O’Rawe AM, Anderson JW, Boustany RM, Lerner TJ, et al. Spectrum of mutations in the Batten disease gene, CLN3. Am J 
Hum Genet. 1997;61(2):310–6. Epub 1997/08/01. pmid:9311735. 
Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell. 1995;82(6):949–57. Epub 1995/09/22. 
pmid:7553855. 
Kovacs AD, Pearce DA. Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile Batten disease. Exp Neurol. 2008;209
(1):288–91. Epub 2007/10/30. pmid:17963751. 
Pontikis CC, Cotman SL, MacDonald ME, Cooper JD. Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model 
of Batten disease. Neurobiol Dis. 2005;20(3):823–36. Epub 2005/07/12. pmid:16006136. 
View Article • PubMed/NCBI • Google Scholar 
18. 
View Article • PubMed/NCBI • Google Scholar 
19. 
View Article • PubMed/NCBI • Google Scholar 
20. 
View Article • PubMed/NCBI • Google Scholar 
21. 
View Article • PubMed/NCBI • Google Scholar 
22. 
View Article • PubMed/NCBI • Google Scholar 
23. 
View Article • PubMed/NCBI • Google Scholar 
24. 
View Article • PubMed/NCBI • Google Scholar 
25. 
View Article • PubMed/NCBI • Google Scholar 
26. 
View Article • PubMed/NCBI • Google Scholar 
27. 
View Article • PubMed/NCBI • Google Scholar 
28. 
View Article • PubMed/NCBI • Google Scholar 
29. 
View Article • PubMed/NCBI • Google Scholar 
30. 
View Article • PubMed/NCBI • Google Scholar 
31. 
View Article • PubMed/NCBI • Google Scholar 
32. 
View Article • PubMed/NCBI • Google Scholar 
Herrmann P, Druckrey-Fiskaaen C, Kouznetsova E, Heinitz K, Bigl M, Cotman SL, et al. Developmental impairments of select neurotransmitter systems in 
brains of Cln3(Deltaex7/8) knock-in mice, an animal model of juvenile neuronal ceroid lipofuscinosis. J Neurosci Res. 2008;86(8):1857–70. Epub 
2008/02/12. pmid:18265413. 
Staropoli JF, Haliw L, Biswas S, Garrett L, Holter SM, Becker L, et al. Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies 
novel early pathology outside the central nervous system. PLoS One. 2012;7(6):e38310. pmid:22701626. 
Kovacs AD, Pearce DA. Location- and sex-specific differences in weight and motor coordination in two commonly used mouse strains. Sci Rep. 
2013;3:2116. Epub 2013/07/03. pmid:23817037. 
Kovacs AD, Pearce DA. Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic 
background and gender. Dis Model Mech. 2015;8(4):351–61. pmid:26035843. 
Nielsen AK, Ostergaard JR. Do females with juvenile ceroid lipofuscinosis (Batten disease) have a more severe disease course? The Danish experience. 
Eur J Paediatr Neurol. 2013;17(3):265–8. pmid:23177590. 
Cialone J, Adams H, Augustine EF, Marshall FJ, Kwon JM, Newhouse N, et al. Females experience a more severe disease course in Batten disease. J 
Inherit Metab Dis. 2012;35(3):549–55. pmid:22167274. 
Golde WT, Gollobin P, Rodriguez LL. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab animal. 2005;34(9):39
–43. Epub 2005/10/01. pmid:16195737. 
Aldrich A, Bosch ME, Fallet R, Odvody J, Burkovetskaya M, Rama Rao KV, et al. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease 
(CLN3). Ann Neurol. 2016;80(6):909–23. pmid:27804148. 
Cotman SL, Mole SE, Kohan R. Future perspectives: Moving towards NCL treatments. Biochim Biophys Acta. 2015;1852(10 Pt B):2336–8. 
pmid:25857620. 
Simon MM, Greenaway S, White JK, Fuchs H, Gailus-Durner V, Wells S, et al. A comparative phenotypic and genomic analysis of C57BL/6J and 
C57BL/6N mouse strains. Genome Biol. 2013;14(7):R82. pmid:23902802. 
Mattapallil MJ, Wawrousek EF, Chan CC, Zhao H, Roychoudhury J, Ferguson TA, et al. The Rd8 mutation of the Crb1 gene is present in vendor lines of 
C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest Ophthalmol Vis Sci. 2012;53(6):2921–7. 
pmid:22447858. 
Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: interactions with laboratory environment. Science. 1999;284(5420):1670–2. 
pmid:10356397. 
Kulesskaya N, Rauvala H, Voikar V. Evaluation of social and physical enrichment in modulation of behavioural phenotype in C57BL/6J female mice. PLoS 
One. 2011;6(9):e24755. pmid:21931844. 
Oliva AM, Salcedo E, Hellier JL, Ly X, Koka K, Tollin DJ, et al. Toward a mouse neuroethology in the laboratory environment. PLoS One. 2010;5
(6):e11359. pmid:20613876. 
Izidio GS, Lopes DM, Spricigo L Jr., Ramos A. Common variations in the pretest environment influence genotypic comparisons in models of anxiety. 
Genes Brain Behav. 2005;4(7):412–9. Epub 2005/09/24. pmid:16176387. 
Sorge RE, Martin LJ, Isbester KA, Sotocinal SG, Rosen S, Tuttle AH, et al. Olfactory exposure to males, including men, causes stress and related 
analgesia in rodents. Nat Methods. 2014;11(6):629–32. Epub 2014/04/30. pmid:24776635. 
33. 
View Article • PubMed/NCBI • Google Scholar 
34. 
View Article • PubMed/NCBI • Google Scholar 
Champy MF, Selloum M, Piard L, Zeitler V, Caradec C, Chambon P, et al. Mouse functional genomics requires standardization of mouse handling and 
housing conditions. Mamm Genome. 2004;15(10):768–83. Epub 2004/11/03. pmid:15520880. 
Klempt M, Rathkolb B, Fuchs E, de Angelis MH, Wolf E, Aigner B. Genotype-specific environmental impact on the variance of blood values in inbred and 
F1 hybrid mice. Mamm Genome. 2006;17(2):93–102. Epub 2006/02/09. pmid:16465589. 
